GLENMARK PHARMACEUTICALS Q2 FY27 CONCALL: TARGETS ₹700–800 CR H2 FY27 OPERATING CASH GENERATION, ZERO GROSS DEBT & ₹1,200 CR NET CASH BY FY27-END; GUIDES $30–40 MN ONCOLOGY REVENUE IN FY28, $100–150 MN BY FY30 & $400–500 MN PEAK SALES BY FY35–36; EXPECTS 15–20% EM GROWTH & MAJOR US RESPIRATORY LAUNCHES